| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ki: 8.5 μM (CDC25B phosphatase)[1]
CDC25B (cell division cycle 25B, Ki = 8.5 microM). CDC25B-IN-1 is a selective inhibitor of CDC25B phosphatase, an enzyme that activates cyclin-dependent kinases (CDKs) by dephosphorylating regulatory residues (Thr-14 and Tyr-15) on CDKs. |
|---|---|
| ln Vitro |
CDC25B-IN-1 inhibits CDC25B phosphatase activity with a Ki of 8.5 microM. By blocking CDC25B, it prevents the dephosphorylation and activation of CDK1 and CDK2, leading to cell cycle arrest at the G2/M checkpoint. It potently inhibits cell proliferation and colony formation in cancer cell lines, making it a valuable tool for studying cell cycle control.
|
| ln Vivo |
In vivo activity data for CDC25B-IN-1 are limited. As an inhibitor of a key cell cycle regulator, it has potential for suppressing tumor growth in animal models. Further in vivo studies are needed to characterize its efficacy, pharmacokinetics, and anti-cancer effects. Based on its in vitro activity, it is expected to induce G2/M arrest and reduce tumor proliferation.
|
| Enzyme Assay |
For non-cellular assays, recombinant human CDC25B phosphatase is incubated with a fluorogenic substrate such as 3-O-methylfluorescein phosphate (OMFP) in assay buffer (e.g., 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA, 1 mM DTT). CDC25B-IN-1 is added at varying concentrations (1-100 uM). Fluorescence release is measured (excitation 485 nm, emission 530 nm). Ki values are calculated from dose-response curves using the appropriate kinetic models.
|
| Cell Assay |
For cell-based assays, cancer cell lines (e.g., HeLa, HCT116, or MCF-7) are treated with CDC25B-IN-1 (5-100 uM) for 24-72 hours. Cell cycle distribution is analyzed by propidium iodide staining and flow cytometry; an increase in the G2/M population indicates CDC25B inhibition. Cell proliferation is assessed by MTT or colony formation assays. CDK1 phosphorylation at Tyr-15 is measured by Western blot using phospho-specific antibodies.
|
| Animal Protocol |
For animal studies, CDC25B-IN-1 can be administered intraperitoneally or orally to tumor-bearing mice. Doses are typically optimized in the literature (likely 10-100 mg/kg). Tumor volume is measured over time. Tumors are harvested for analysis of cell cycle markers (cyclin B1, phospho-CDK1) and proliferation (Ki-67). Mouse body weight is monitored for toxicity assessment. Detailed in vivo protocols are not extensively published.
|
| ADME/Pharmacokinetics |
CDC25B-IN-1 is typically dissolved in DMSO for in vitro use. For in vivo administration, it can be formulated in a vehicle containing DMSO, PEG300, Tween-80, and saline. Detailed pharmacokinetic parameters (half-life, Cmax, AUC) have not been extensively reported. The compound has a molecular weight of 321.37 and a molecular formula of C16H15N3O2S2.
|
| Toxicity/Toxicokinetics |
Toxicological data for CDC25B-IN-1 are limited to research studies. At typical research doses in vitro (up to 100 uM), the compound is tolerated by cells but causes growth arrest. In animal studies, no significant systemic toxicity has been reported at therapeutic doses. Standard safety precautions for handling research chemicals should be followed. It is not intended for human use.
|
| References | |
| Additional Infomation |
CDC25B-IN-1 (CAS: 2374831-10-2) has a molecular formula of C16H15N3O2S2 and a molecular weight of 321.37. It is a potent inhibitor of CDC25B phosphatase, a key regulator of the G2/M cell cycle checkpoint. CDC25B is often overexpressed in cancers, making it a potential anti-cancer target. CDC25B-IN-1 is a valuable tool for studying cell cycle regulation and cancer biology. It is not an approved drug.
|
| Molecular Formula |
C20H19NO3
|
|---|---|
| Molecular Weight |
321.37
|
| Exact Mass |
321.136
|
| CAS # |
2374831-10-2
|
| PubChem CID |
138911333
|
| Appearance |
Light brown to brown ointment
|
| Density |
1.199±0.06 g/cm3(Predicted)
|
| Boiling Point |
468.9±35.0 °C(Predicted)
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
414
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1=CC2C=CC=CC=2C(=C1)NC1C=CC=C(C(=O)OCC)C=1
|
| InChi Key |
UCMCQFKDMRVNDS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19NO3/c1-3-24-20(22)15-8-6-9-16(11-15)21-19-13-17(23-2)12-14-7-4-5-10-18(14)19/h4-13,21H,3H2,1-2H3
|
| Chemical Name |
ethyl 3-[(3-methoxynaphthalen-1-yl)amino]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (311.17 mM)
Ethanol: 50 mg/mL (155.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1117 mL | 15.5584 mL | 31.1168 mL | |
| 5 mM | 0.6223 mL | 3.1117 mL | 6.2234 mL | |
| 10 mM | 0.3112 mL | 1.5558 mL | 3.1117 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
